REPROCELL
Miho Kenny has extensive experience in marketing communications, sales, and education. Currently serving as the Marketing Communications Manager at REPROCELL since October 2014, Miho is engaged in various aspects of marketing, including trade show coordination and CRM management, while also providing customer support and handling e-commerce operations. In addition to this role, Miho has been a 4th Grade Head Teacher at the Japanese Language School of Greater Boston since 2003, teaching Japanese and mathematics to diverse student populations. As a Freelance Healthcare Interpreter and Language Coach since 2008, Miho provides interpretation services in healthcare settings and conducts training sessions. Miho also works as a Freelance Technical & Academic Japanese Interpreter/Translator for a biotechnology company and has experience in sales and marketing administration for ReproCELL USA Inc. Miho holds a Bachelor of Arts degree in Linguistics with a focus on English/Spanish and International Business from Northeastern University and Kobe City University of Foreign Studies.
This person is not in any offices
REPROCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES/ iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.